



Review Article

Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review

Danielle Aparecida de Oliveira Marrafon¹, Alessandra Oliveira Silva^{1,*},
 Ana Flávia Amorim¹, Carlos Marcelo de Barros², Ricardo Radighieri Rascado¹,
 Carla Speroni Ceron³, Tiago Marques dos Reis¹,
 Márcia Helena Miranda Cardoso Podestá¹, Daniel Augusto de Faria Almeida¹,
 Larissa Helena Torres¹, Marília Gabriella Alves Goulart Pereira¹

¹Federal University of Alfenas, Brazil

²Santa Casa de Alfenas, Brazil

³Federal University of Ouro Preto, Brazil



ARTICLE INFO

Article history:

Received 22-03-2023

Accepted 15-06-2023

Available online 19-07-2023

Keywords:

Adverse effects

Chronic pain

Oxidative stress

Pharmacology

Tapentadol

Analgesics

Antioxidants

Opioid

ABSTRACT

Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a μ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

According to the World Health Organization (WHO), chronic pain affects 30 % of the population.¹ It is one of the main causes of absence from work and retirement due to illness, as it limits physical functions, simple day-to-day activities, and interpersonal relationships, significantly interfering in people's quality of life¹⁻³ Furthermore, pain is a serious public health problem and leads to an economic burden of medical expenses, lost wages, and reduced productivity.^{3,4}

Usually, chronic pain is caused by some diseases, such as osteoarthritis, rheumatoid arthritis, osteoporosis, low back pain, and fibromyalgia. However, pain of any etiology that remains for more than three months can be considered chronic, if it is not directly related to neoplasms.³ It can be classified as nociceptive or neuropathic: nociceptive pain arises due to tissue injury or inflammation and neuropathic pain occurs due to a dysfunction of the nervous system, which may be in the brain, spinal cord, or peripheral nerves, being common to appear in the form of burning, needling, or tingling.²

Furthermore, chronic pain induces neuroinflammation, neuroplasticity and neurodegeneration, which can extend and increase the pain signal. Pain information is relayed

* Corresponding author.

E-mail address: alessandra.silva@sou.unifal-mg.edu.br (A. O. Silva).

from one neuron to another, creating a persistent “memory” of an aggressive event and neuronal hyperexcitability. Therefore, its intensity increases, so that pain does not depend only on an injury to organs or tissues, but on a complex change in the sensory processing of the nervous system.^{5,6} In addition, pain is perceived by brain circuits linked to emotions, so it may be related to depression and be the cause and consequence of it. Thus, some myalgias improve with the use of antidepressant medications, or with measures that act on the emotional state and response to stress.⁷

Several pharmacological treatments have been used to control or try to prevent the spread of the pain signal. However, they cause many adverse effects that impair adherence to treatment. Moreover, most chronic pain patients also report that severe pain is not adequately controlled by prescribed medications, which exacerbates the negative impacts of this condition. Therefore, the search for safe and effective drugs to treat severe chronic pain is one of the multiple challenges in pain management.^{2,3}

Tapentadol is an opioid analgesic similar to tramadol and has been used effectively to treat pain.^{6–8} This drug has a high affinity for opioid receptors, in addition to acting to inhibit the reuptake of NA (nor epinephrine).^{2,6,9,10} The Tapentadol therapeutic profile allows for a more potent action, with greater tolerability by the patient, reducing the emergence of respiratory, gastrointestinal and endocrine disorders^{11,12}, being mainly nausea and vomiting, which have higher incidences with opioids such as Tramadol or Oxycodone.^{13–16} In contrast, studies indicate that Tapentadol can imbalance the antioxidant system, leading to an increase in reactive oxygen species (ROS), which can favor the emergence of various pathologies or even increased pain.^{17–19} Therefore it is essential to know the drug better so that possible undesirable effects are detected.

Thus, the focus of this review is to address the main mechanisms involved in Tapentadol action and its side effects. In addition, we focus on the possible oxidative process that may occur with chronic use of this drug and whether the use of antioxidant compounds can reverse or help prevent this process, as observed in studies with other opioids.

Therefore an active literature search was performed using the terms "Tapentadol and chronic pain", "Tapentadol and oxidative stress", "Tapentadol and antioxidants", and "Tapentadol and clinical studies". The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google scholar databases, with no data and language restriction. In addition, filters were not used. The search was carried out on December 16, 2022. The selected articles were those dealing with the use of Tapentadol for chronic moderate to severe pain, unrelated to cancer pain, encompassing only use in adults (more than 18 years old), and the elderly (more than 60 years old). The analysis of

the information began with the title and abstract, and later, if the article met the inclusion criteria, general analysis was carried out.

2. Discussion

2.1. Chronic pain and opioids

Chronic pain treatment is based on the WHO Analgesic Scale. Non-opioid analgesics, followed by selective COX-2 (cyclooxygenase) inhibitors and non-steroidal anti-inflammatory drugs are used to treat low-intensity pain. Opioids, such as morphine and oxycodone, can be combined with other analgesics for moderate to severe pain when other medications are not adequate to promote analgesia.^{3,20,21} Adjuvant analgesics such as antidepressants or anticonvulsants are also used.²⁰

Although opioids are potent analgesics, their prescription for the treatment of chronic pain should be cautious due to adverse effects and the risk of developing tolerance.²¹ Nausea, vomiting, constipation, and drowsiness are common adverse effects that lead to the use of inadequate doses or discontinuation of therapy, which compromises the efficiency of the treatment.^{2,5} Determining the correct dose of co-administered analgesics to optimize the efficacy and tolerability of pain management is a major clinical challenge, as many patients find it difficult to adhere to multiple medications. Thus, the use of only one safe and effective drug, covering the various pathophysiological mechanisms of pain, would be ideal for long-term treatment. Therefore, the implementation of safer drugs with fewer adverse effects becomes essential. In this context, Tapentadol has been studied as a promising alternative in the treatment of chronic pain.²

2.2. Tapentadol

Tapentadol was approved by the FDA (Food and Drug Administration) in November 2008 and since then, its immediate-release formulation has been marketed in the United States for the treatment of moderate to severe acute pain. The extended-release version has been used since 2011 for the treatment of moderate to severe chronic pain.^{6–8} In Europe, the commercialization of immediate and extended-release formulations was approved in 2010 by the EMA (European Medicines Agency).⁶ The extended-release formulation is indicated for patients with chronic pain who require long-term analgesic treatment, as it allows a frequent dose with better pain management.²

This opioid analgesic is structurally similar to tramadol, but more potent and better tolerated.^{2,6} Its dual mechanism of action provides analgesia similar to potent narcotic analgesics such as oxycodone and morphine, however, it shows a lower incidence of side effects.^{2,4,6}

In preclinical studies, the affinity of Tapentadol to μ opioid receptor was found to be approximately 50 times

lower than that of morphine, but the *in vivo* analgesic potency of Tapentadol was only two to three times lower than that of morphine in rat models, suggesting that Tapentadol may have weaker μ -receptor related side effects than classical opioids at equianalgesic doses.²² Its chronic use was associated with a low incidence of constipation, showing a better gastrointestinal tolerability profile than oxycodone, tramadol, fentanyl, morphine, hydromorphone, buprenorphine, and oxymorphone.¹⁷

Tapentadol may also be an analgesic option for patients who do not respond adequately to commonly used opioids, due to genetic disposition (weak CYP450 (cytochrome)) metabolizers, as it does not depend on metabolism to produce its therapeutic effects.^{2,6,17,23} Its inactive metabolites do not exert activities on opioid receptors or synapse reuptake systems, in addition to not demonstrating induction or significant inhibition of CYP 450. Therefore, it does not cause clinically relevant changes in pharmacokinetic properties when administered with other drugs such as omeprazole and metoclopramine.⁶

2.3. Pharmacodynamic

Opioids are agonists of one or more of the three major opioid receptors: μ , δ (Delta), and κ (Kappa) opioid receptors. These receptors are transmembrane and G protein-coupled and are located along the pain pathways in the central nervous system. The activation of these receptors inhibits transmission, decreasing the release of presynaptic neurotransmitters and hyperpolarization of postsynaptic neurons.^{2,21,24}

The μ opioid receptors can be found in the amygdala and nucleus accumbens and are responsible for the state of euphoria and reward, in addition to their agonists promoting a powerful analgesic effect.^{25,26} Tapentadol has up to ten times greater affinity to μ compared to δ and κ opioid receptors.¹⁴ *In vitro* studies have shown that the affinity of Tapentadol to μ is considerably lower than that of classic opioids such as morphine.^{5,27}

Tapentadol produces the analgesic effect, acting both in the descending and ascending path of pain.²⁸ The μ effect of Tapentadol blocks ascending pain signals in the spinal cord, activating the descending inhibition of supraspinal projections, while the increase in the concentration of NA leads to descending inhibition of this pathway.¹² This evidence is confirmed by Kogel et al.²⁹ who observed that knockout mice with genetic μ deletion showed a partial decrease in the analgesic efficacy of Tapentadol. Another study by Meske et al.³⁰ quantified the NA concentration in the cerebrospinal fluid of rats with spinal nerve ligation or sham surgery, which received morphine, Tapentadol and duloxetine, intraperitoneally. Tapentadol has shown a significant increase in spinal NA, relating to its clinical efficacy in analgesia. Schröder et al.³¹ suggest, in studies with rodents, that analgesia produced by Tapentadol in

acute nociceptive pain is due to its μ agonism, while in chronic neuropathic pain, it is due to noradrenaline reuptake inhibition (NRI).

By blocking NA reuptake, Tapentadol increases the level of this neurotransmitter in spinal synapses and interrupts pain signaling by activating adrenoreceptors in postsynaptic spinal nociceptive neurons. *In vivo* and *in vitro* studies show that Tapentadol restores the descending inhibitory control of pain.²⁸

Tapentadol still has a greater inhibitory effect on NA reuptake, which can reach approximately 450 %, while in relation to serotonin levels, this is around 150 %. *In vitro* and *in vivo* studies using Wistar rats, showed that this effect is due to greater inhibition of NA transporters compared to serotonin.³² With minimal serotonergic activity, Tapentadol proves to be tolerable for chronic therapy since the activity of serotonergic pathways is analgesic and stimulates vomiting.^{32,33}

Moreover, Tramadol is the drug with the greatest similarity with the mechanism of action of Tapentadol, but it has serotonergic properties, and the presence of enantiomers with different actions reduces its synergism of activity.¹³ Serotonin syndrome is characterized by excessive activation of central and peripheral serotonergic receptors, with neuro-excitatory characteristics.³⁴ There is only a theoretical relationship between the occurrence of this syndrome and the administration of Tapentadol, since the evidence in the literature was insufficient.²⁷ Currently, no additional mechanisms are observed to be involved in the analgesic action of Tapentadol, as the spinal application of opioid receptors and selective antagonists of adrenergic receptors completely reversed the inhibitory effects of Tapentadol.²⁸

In relation to undesirable effects, in general this drug is well tolerable, with reduced unwanted respiratory, gastrointestinal, and endocrine effects related to the adverse effects of opioids.^{11,12,35} Therefore, patients who use Tapentadol are less likely to develop an adverse effect and discontinue treatment than those who are treated with other opioids, such as buprenorphine, oxymorphone, oxycodone, hydromorphone, and morphine.³⁶

Studies associate adverse effects to Tapentadol such as: abdominal pain, electrolyte anomaly, atrial fibrillation, suspension, tremor, miosis, hypotension, convulsions, tachycardia, hypertension, delirium, hallucination, convulsion, respiratory depression, reaching coma and death. The most common are vomiting, dizziness, headache, and drowsiness.³⁷ As mentioned above, Tapentadol promotes less activation of μ receptors compared to classic opioids, eliminating a lower incidence of unwanted effects. However, most adverse reactions observed with the use of this drug are related to the wide expression of the μ in different devices and organs.³⁵

In relation to nausea and vomiting, studies show that the better tolerability of Tapentadol is related to its reduced opioid action, in addition to the minimal serotonergic activity, but it is not related to NRI.³⁸ On the contrary, the reduction of physical dependence is closely linked to this second drug mechanism, despite the reduced opioid activity also presented.¹³ Nausea and constipation with the use of Tapentadol is less frequent than with other opioids.^{36,39,40} These data can be confirmed in animal models and in clinical studies. When Tapentadol was applied intraperitoneally in high doses, it led to a lower incidence of nausea in ferrets, whereas with the use of morphine in low doses, animals develop intense nausea. As for constipation, in mice in diarrhea models, the potency ratio to produce an analgesic action and constipation was more favorable to Tapentadol compared to morphine. These studies were confirmed in patients who were administered Tapentadol and oxycodone, demonstrating that the former produces less nausea, vomiting and constipation.^{13,14,39} Regarding dependence, Tapentadol is less likely compared to other opioids.⁴⁰

Classic opioids have adverse effects, such as respiratory depression and constipation related to analgesic effects, that is, they are one-dimensional and their therapeutic and adverse effects are due to μ agonism.¹¹ Respiratory depression is particularly important in centrally acting drugs as they can be fatal. It is associated with direct activation of opioid receptors on brainstem neurons. This condition has been reported in clinical trials with Tapentadol, being evidenced only in high dose administrations or in patients related to μ agonists, leading to discontinuation of treatment in only 15 % of cases^{5,14,27,41} Channell et al.³⁷ identified in the literature at least four deaths associated with respiratory depression with the use of this analgesic. However, this adverse reaction may be related to the presence of previous respiratory problems.

Regarding other adverse reactions, Tapentadol minimally acts on the hypothalamic-pituitary-gonadal axis in a way that has a lower impact on the concentration of sex hormones than morphine or oxycodone.⁴² The NRI activity of Tapentadol contributes so that no dysfunction in adult neurogenesis and other associated functions, such as memory, is observed, as this action neutralizes the adverse effect mediated by μ .⁴³ In a study developed by Biondi et al.⁴⁴ in hypertensive patients who used Tapentadol for chronic pain, no clinical changes in mean blood pressure and cardiac function were observed. According, Oh et al.⁴⁵ subtherapeutic and therapeutic doses of Tapentadol also did not change the QT/QTc interval in healthy subjects.

2.4. Clinical studies

Tapentadol has been shown to be effective and well tolerated in most chronic painful conditions.⁴⁶ In the recent observational and cross-sectional study by Barrachina et

al.⁴⁷, Tapentadol was shown to have a lower MEDD (Morphine-Equivalent Daily Dose) (89 ± 88 mg/day) than oxycodone/naloxone (124 ± 109 mg/day), in addition to presenting fewer undesirable effects and better tolerability in patients with chronic pain not associated with cancer.

In a randomized clinical study with more than 900 patients after orthopedic surgery, Tapentadol IR (Immediate Release) 50 mg and 75 mg, placebo, and oxycodone IR 10 mg were compared in terms of effectiveness and safety in acute pain. These drugs were administered every 4-6 hours until 72 hours after surgery. Compared to placebo, Tapentadol was shown to significantly improve moderate and acute pain, whereas in relation to oxycodone, Tapentadol, at the two doses tested, did not show inferior effectiveness to this opioid. Regarding undesirable effects such as nausea and vomiting, Tapentadol had a significantly lower incidence.³⁹ Similarly, Taiwanese⁴⁸ and Korean⁴⁹ patients after bunionectomy when receiving Tapentadol IR 50 or 75 mg or placebo orally every 4-6 hours for a period of 72 hours, showed a reduction in the intensity of acute pain compared to placebo.

Analyzing 258 patients with low back pain, the efficacy of Tapentadol (250 mg) was compared with oxycodone/naloxone (40 mg/20 mg) and a greater reduction in pain and greater gastrointestinal tolerability was observed.⁵⁰ These results corroborate the findings of Biondi et al.⁵¹ with 585 patients with acute, moderate to severe pain, showing similar analgesic effectiveness to oxycodone. Biondi et al.⁵² also demonstrated greater tolerability of this drug in elderly people aged 75 years and over, with a diagnosis of knee osteoarthritis or low back pain in relation to oxycodone.

In this sense, a study carried out in four countries (Australia, Canada, New Zealand, and the United States), involving 1030 patients with chronic knee pain derived from osteoarthritis, observed that the use of Tapentadol for 12 weeks showed better efficacy and lower incidence of undesirable effects comparable to oxycodone, thus presenting a better safety profile.⁵³ These data corroborate the studies by Lange (2017) carried out in the United States that found better efficacy and safety associated with Tapentadol. In addition, Tapentadol (100-250 mg) promoted improvement in pain and was well tolerated compared to placebo over three⁵⁴ and twelve weeks⁵⁵ in patients with diabetic peripheral neuropathy, being an alternative to this health problem.

Furthermore, patients who underwent the substitution of opioids by Tapentadol were followed in the study by Gálvez et al.⁵⁶ Tapentadol analgesia (50-250 mg twice daily) was compared to opioids such as oxycodone, buprenorphine, fentanyl, morphine, and hydromorphone and showed comparable pain relief. The main undesirable effects of opioids such as nausea and vomiting were reduced with the use of this analgesic.

In moderate to severe pain associated with malignant tumors, Tapentadol (100-250 mg) showed comparable efficacy to morphine (40-100 mg) over two weeks, but with fewer gastrointestinal undesirable effects.⁵⁷ In this same clinical condition, 233 Japanese and Korean patients who received Tapentadol (200 mg) showed efficacy comparable to another opioid, oxycodone (40 mg), and similarly a lower incidence of undesirable effects.⁵⁸

2.5. Oxidative stress

In addition, recent evidence suggests that opioids can act directly on the antioxidant defense.⁵⁹ Toxicity studies show that chronic treatment for 21 days of rodents with morphine⁶⁰ and codeine⁶¹ is able to decrease superoxide dismutase (SOD) and catalase (CAT) activities and increase malonaldehyde (MDA) in the brain of these animals.

Toxicity studies with acute doses of morphine have shown depletion of GSH (Glutathione Reductase) levels in the brain of rodents.⁶² Codeine, in turn, in chronic use for six weeks to assess its toxicity, increased MDA, and myeloperoxidases and decreased GSH levels and SOD and CAT activities in liver tissues.⁶³ In humans, the use of buprenorphine and methadone decrease plasma levels of GSH and CAT and enhance MDA in patients on heroin maintenance therapy.⁶⁴

In relation to tramadol, this compound can increase oxidative stress by regulation of dopamine levels with consequent release of hydrogen peroxide rodent brain mitochondria.⁶⁵ In studies of toxicity in which Wistar rats were subjected to doses of 40 or 200 mg/kg/day of tramadol for approximately one month, the opioids demonstrated a decrease in antioxidant enzymes and an increase in MDA levels in the brain and plasma of rodents. Furthermore, the association of antioxidants with tramadol such as thyme in the dose of 500 mg/kg for 30 days or fennel incorporated into rodent diets at concentrations of 10, 20 and 30 % for six weeks led to a reduction in these damages. The damage caused by Tapentadol to organs such as the brain, heart, and lungs of rodents is believed to be related to tramadol-like mechanisms.¹⁸

In this regard, chronic administration of Tapentadol in Wistar rats for 14 days at doses of 10, 25, and 50 mg/kg is related to changes in lipid peroxidation levels in the liver, kidney, heart, lung, liver, and brain of these animals.⁶⁶ Furthermore, Tapentadol induced an increase in protein oxidation due to the elevation of carbonyl groups in the liver, kidney⁶⁶, and brain⁶⁷ of these animals and a decrease in the total antioxidant capacity in the liver.⁶⁶

Studies using Wistar rats in acute exposure to a single dose of 10, 25, or 50 mg/kg decreased substances reactive to thiobarbituric acid (TBARS) levels in liver and kidney. However, the same studies revealed significant increases in protein carbonyl groups of these tissues, indicating an induction of oxidation at the protein level. Therefore, the

decrease in TBARS levels may be related to a protective effect or up-regulation of enzymes, to prevent oxidative damage. Consequently, the role of this drug in the formation of oxidative stress cannot be ruled out.¹⁸

Additionally, a study with cultures of neuronal cells treated with a concentration of 100 μ M (micromole) and 200 μ M of Tapentadol demonstrated that this drug promotes a decrease in metabolic activity, mainly by decreasing ATP (Adenosine Triphosphate) levels, which is closely linked with enzymatic and metabolic changes.¹⁷ Neuronal damage is observed through darker colored neurons and glial activation with microglial proliferation and the presence of inflammatory infiltrates in cardiac, pulmonary¹⁸, and renal⁶⁸ tissue.

In this context, the antioxidant system is mainly formed by the enzymes SOD, CAT, and GPx (Glutathione Reductase), which together play an important role in maintaining the body's balance, neutralizing ROS and thus preventing tissue and cell damage. However, in situations of oxidative stress there is an increase in oxidizing compounds and dysregulation in the activities of these enzymes, leading to various damages.⁶⁹

The presence of oxidative stress is detected in animals by the dosage of antioxidant enzymes and MDA, which is the main marker of lipid peroxidation, which is determined through the technique of reactive species to TBARS.⁶⁹ In humans, this detection occurs through biomarkers, which are indicators of normal and pathogenic biological processes or pharmacological response to a therapy.^{70,71}

According to Gunn et al.⁷⁰, oxidative stress markers in humans correspond to pyroglutamate and ethylmalonic acid, and ethylmalonic acid, and mainly indicate glutathione depletion, deficiency of coenzyme Q10, Vitamin B12 and/or carnitine, respectively. Thus, high levels of pyroglutamate, for example, indicate that the cell is more susceptible to oxidative damage by reducing glutathione.

Vitamin B12 has several functions in the body, including the elimination of free radicals, as well as the preservation of glutathione. In this sense, its reduction becomes an important mechanism to identify a higher percentage of pro-oxidant compounds; and studies demonstrate that vitamin B12 supplementation leads to decreases in ROS, especially the superoxide anion.^{72,73}

Additionally, Vecchiet et al.¹⁹ observed that free radicals are associated with hyperalgesia, and therefore, the maintenance of glutathione levels is essential for the management of chronic pain. Thus, the monitoring of patients who use drugs that can increase ROS levels, such as Tapentadol, need monitoring, as do the associations with antioxidant compounds, which are substances capable of inhibiting or delaying the damage caused by oxidizing agents.⁶⁹

Therefore further studies are needed to clarify the relationship of oxidative stress in the use of Tapentadol,

especially in chronic use. Thus, it would be crucial to associate the use of this drug concomitantly with antioxidants, as was done with tramadol, to determine whether the results found will be the same and whether the antioxidants will act to improve the inflammatory infiltrates found in the use of Tapentadol, since most antioxidant compounds also have anti-inflammatory activity.^{69,72,74}

3. Conclusions

Tapentadol is a promising drug in the treatment of acute and chronic pain, as it has better tolerability of use by the patient. In addition, its dual mechanism of action allows the use of an effective monotherapy, facilitating medication adherence and making it safer, since the use of a single drug to promote analgesia can reduce the incidence of side effects.

However some issues need to be clarified, as biochemical abnormalities such as vitamin B12 deficiency can compromise the analgesic efficacy of drugs such as Tapentadol, leading to hyperalgesia or the need for concomitant supplementation of antioxidants to neutralize the production of free radicals and favor the action of this analgesic.

Thus, more studies need to be carried out to determine the safety of the chronic use of Tapentadol, as this drug simulates other drugs that lead to severe oxidative damage “in vivo”. Given the possibility of harmful effects to the body with its use, the therapeutic follow-up of patients is essential in clinical practice.

4. Source of Funding

None.

5. Conflict of Interest

None.

Acknowledgments and Funding

The authors acknowledge the support by Coordination of Superior Level Staff Improvement, Brasil (CAPES, Finance Code 001).


References


- Santos LMC, Almeida LGR, Faro A. Autoeficácia e Locus de Controle na Adesão ao Tratamento de Pessoas Hipertensas. *Rev Psicol e Saúde*. 2019;11(3):49–62.
- Águila SD, Schenk MJ, Kern M. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. *Clin Ther*. 2015;37(1):94–113.
- Taylor R, Pergolizzi JV, Raffa RB. Tapentadol extended release for chronic pain patients. *Adv Ther*. 2013;30:14–27.
- Obradovic M, Ikenberg R, Hertel N. Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs. *Clin Ther [Internet]*. 2012;34:926–43.
- Deeks ED. Tapentadol Prolonged Release: A Review in Pain Management. *Drugs*. 2018;78:1805–16.
- Mosele BDM, Almeida DB, Hess VB. Tapentadol: what every doctor needs to know about this new drug. *Brazilian J Pain*. 2018;1(1):72–6.
- Eisenberger NI. The neural bases of social pain: Evidence for shared representations with physical pain. *Psychosom Med*. 2012;74(2):126–35.
- Hartrick CT, Hernandez R. Tapentadol for pain: A treatment evaluation. *Expert Opin Pharmacother*. 2012;13:283–6.
- Baron R, Eberhart L, Kern KU. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data. *Pain Pract*. 2017;17:678–700.
- Caputi FF, Nicora M, Simeone R. An analgesic that differs from classic opioids due to its noradrenergic mechanism of action. *Minerva Med*. 2019;110(1):62–78.
- Raffa RB, Elling C, Tzschentke TM. Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘ μ -Load’. *Adv Ther*. 2018;35(10):1471–84.
- Coluzzi F, Polati E, Freo U. An effective option for the treatment of back pain. *J Pain Res*. 2019;12:1521–8.
- Tzschentke TM, Christoph T, Kögel BY. The Mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: The case of tapentadol. *CNS Drugs*. 2014;28:319–29.
- Singh DR, Nag K, Shetti AN. Tapentadol hydrochloride: A novel analgesic. *Saudi J Anaesth*. 2013;7(3):322–6.
- Tzschentke TM, Christoph T, Schröder W. Mit zwei Mechanismen in einem Molekül wirksam gegen nozizeptive und neuropathische Schmerzen: Präklinischer Überblick. *Schmerz*. 2011;25(1):19–25.
- Daniels S, Casson E, Stegmann JU. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. *Curr Med Res Opin*. 2009;25(6):1551–61.
- Faria J, Barbosa J, Queirós O. Comparative study of the neurotoxicological effects of tramadol and tapentadol in SH-SY5Y cells. *Toxicology*. 2016;359:1–10. doi:10.1016/j.tox.2016.06.010.
- Faria J, Barbosa J, Leal S. Effective analgesic doses of tramadol or tapentadol induce brain, lung and heart toxicity in Wistar rats. *Toxicology*. 2017;385:38–47.
- Vecchiet J, Cipollone F, Falasca K. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. *Neurosci Lett*. 2003;335:151–4.
- Olivência SA, Barbosa LGM, Cunha MR. Tratamento farmacológico da dor crônica não oncológica em idosos: Revisão integrativa. *Rev Bras Geriatr e Gerontol*. 2018;21:372–81.
- Pergolizzi J, Alegre C, Blake D. Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol. *Pain Pract*. 2012;12:290–306.
- Chang EJ, Choi EJ, Kim KH. Tapentadol: Can it kill two birds with one stone without breaking windows? *Korean J Pain*. 2016;29(3):153–7.
- Barbosa J, Faria J, Queirós O. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. *Drug Metab Rev*. 2016;48(4):577–92.
- Atwoli L, Stein DJ, Koenen KC. Epidemiology of posttraumatic stress disorder: Prevalence, correlates and consequences. *Curr Opin Psychiatry*. 2015;28(4):307–11.
- Wang S. Historical Review: Opiate Addiction and Opioid Receptors. *Cell Transplant*. 2019;28(3):233–8.
- Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. *Neuro psychopharmacol*. 2018;43(14):2514–20.
- Stollenwerk A, Sohns M, Heisig F. Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic. *Adv Ther*. 2018;35(1):12–30.
- Romualdi P, Grilli M, Canonico PL. Pharmacological rationale for tapentadol therapy: A review of new evidence. *J Pain Res*. 2019;12:1513–20. doi:10.2147/JPR.S190160.
- Kögel B, Vry D, Tzschentke J. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ -opioid receptor) knockout mice. *Neurosci Lett*. 2011;491(2):104–7.

30. Meske DS, Xie JY, Oyarzo J. Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. *Neurosci Lett*. 2014;562:91–6.
31. Schröder W, Vry D, Tzschentke J. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. *Eur J Pain*. 2010;14(8):814–21.
32. Tzschentke TM, Christoph T, Kögel B. 1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl): A novel μ -opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. *J Pharmacol Exp Ther*. 2007;323:265–76.
33. Tzschentke TM, Folgering J, Flik G. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. *Neurosci Lett*. 2012;507(2):151–5.
34. Edelstein CS, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. *Expert Opin Drug Saf*. 2008;7(5):587–96.
35. Polati E, Canonico PL, Schweiger V. Tapentadol: an overview of the safety profile. *J Pain Res*. 2019;12:1569–76.
36. Freynhagen R, Elling C, Radic T. Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials. *Curr Med Res Opin*. 2021;37(1):89–100.
37. Channell JS, Schug S. Toxicity of tapentadol: a systematic review. *Pain Manag*. 2018;8(5):327–39.
38. Cowan A, Raffa RB, Tallarida CS. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. *Eur J Pain (United Kingdom)*. 2014;18:1148–56.
39. Daniels SE, Upmalis D, Okamoto A. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. *Curr Med Res Opin*. 2009;25(3):765–76.
40. Zajączkowska R, Przewłocka B, Kocot-Kępska M. Tapentadol - A representative of a new class of MOR-NRI analgesics. *Pharmacol Rep*. 2018;70(4):812–20.
41. Hartrick CT, Rozek RJ. Tapentadol in Pain Management. *CNS Drugs*. 2011;25:359–70.
42. Eichenbaum G, Göhler K, Etropolski M. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. *J Opioid Manag*. 2015;11(3):211–27.
43. Bortolotto V, Grilli M. Opiate analgesics as negative modulators of adult hippocampal neurogenesis: Potential implications in clinical practice. *Front Pharmacol*. 2017;8:1–7. doi:10.3389/fphar.2017.00254.
44. Biondi DM, Xiang J, Etropolski M. Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: A post hoc, pooled data analysis. *Clin Drug Investig*. 2014;34(8):565–76.
45. Oh C, Rengelshausen J, Mangold B. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. *Int J Clin Pharmacol Ther*. 2010;48(10):678–87.
46. Mateos RG, Bernal DS, Morera LMT. Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release. *Pain Physician*. 2021;24(1):75–85.
47. Barrachina J, Margarit C, Muriel J. Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study. *Sci Rep*. 2022;12(1):1–12. Available from: <https://doi.org/10.1038/s41598-022-13085-5>.
48. Chen YJ, Chiang CC, Huang PJ. Tapentadol immediate-release for acute postbunionectomy pain: A phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan. *Curr Med Res Opin*. 2015;31:2001–9.
49. Lee YK, Ko JS, Rhim HY. Acute postoperative pain relief with immediate-release tapentadol: Randomized, double-blind, placebo-controlled study conducted in South Korea. *Curr Med Res Opin*. 2014;30:2561–2570.
50. Baron R, Likar R, Mola EM. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. *Pain Pract*. 2016;16:580–99.
51. Biondi D, Xiang J, Benson C. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. *Pain Physician*. 2013;16(3):E237–46.
52. Biondi DM, Xiang J, Etropolski M. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. *J Opioid Manag*. 2015;11(5):393–403.
53. Afilalo M, Etropolski MS, Kuperwasser B. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo-and active-controlled phase III study. *Clin Drug Investig*. 2010;30(8):489–505.
54. Schwartz S, Etropolski M, Shapiro DY. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. *Curr Med Res Opin*. 2011;27(1):151–62.
55. Vinik AI, Shapiro DY, Rauschkolb C. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. *Diab Care*. 2014;37(8):2302–9.
56. Gálvez R, Schäfer M, Hans G. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: Results of an open-label, phase 3b study. *Adv Ther*. 2013;30(3):229–59.
57. Kress HG, Koch ED, Kosturski H. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. *Pain Physician*. 2014;17(4):329–43.
58. Imanaka K, Tominaga Y, Etropolski M. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. *Curr Med Res Opin*. 2013;29(10):1399–409.
59. Sadat-Shirazi MS, Zarrindast MR, Ashabi G. Oxidative stress enzymes are changed in opioid abusers and multidrug abusers. *J Clin Neurosci*. 2020;72:365–9.
60. Sumathi T, Nathiya VC, Sakthikumar M. Protective effect of bacoside-A against morphine-induced oxidative stress in rats. *Indian J Pharm Sci*. 2011;73(4):409–15.
61. Archibong VB, Ekanem T, Igiri A. The effect of codeine administration on oxidative stress biomarkers and the expression of the neuron-specific enolase in the brain of Wistar rats. *Naunyn Schmiedeberg Arch Pharmacol*. 2021;394(8):1665–73.
62. Guzmán DC, Vázquez IE, Brizuela NO. Assessment of oxidative damage induced by acute doses of morphine sulfate in postnatal and adult rat brain. *Neurochem Res*. 2006;31(4):549–54.
63. Akhigbe RE, Ajayi LO, Adelakun AA. Codeine-induced hepatic injury is via oxido-inflammatory damage and caspase-3-mediated apoptosis. *Mol Biol Rep*. 2020;47:9521–30.
64. Leventelis C, Goutzourelas N, Kortsinidou A. Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood. *Oxid Med Cell Longev*. 2019;p. 9417048. doi:10.1155/2019/9417048.
65. Bameri B, Shaki F, Ahangar N. Evidence for the Involvement of the Dopaminergic System in Seizure and Oxidative Damage Induced by Tramadol. *Int J Toxicol*. 2018;37(2):164–70.
66. Barbosa J, Faria J, Garcez F. Repeated administration of clinical doses of tramadol and tapentadol causes hepato-and nephrotoxic effects in wistar rats. *Pharmaceuticals*. 2020;13(7):1–36.
67. Barbosa J, Faria J, Garcez F. Repeated administration of clinically relevant doses of the prescription opioids tramadol and tapentadol causes lung, cardiac, and brain toxicity in wistar rats. *Pharmaceuticals*. 2021;14(2):1–34.
68. Barbosa J, Faria J, Leal S. Acute administration of tramadol and tapentadol at effective analgesic and maximum tolerated doses causes hepato- and nephrotoxic effects in Wistar rats. *Toxicology*. 2017;389:118–29.
69. Kumar S, Gupta E, Kaushik S. Evaluation of oxidative stress and antioxidant status: Correlation with the severity of sepsis. *Scand J*


- Immunol.* 2018;87(4):1–11.
70. Gunn J, Hill MM, Cotton BM. An analysis of biomarkers in patients with chronic pain. *Pain Physician.* 2020;23(1):41–9.
 71. Kalso E. Biomarkers for pain: See related article by. *Pain.* 2004;107:199–201.
 72. Misra UK, Kalita J, Singh SK. Oxidative Stress Markers in Vitamin B12 Deficiency. *Mol Neurobiol.* 2017;54:1278–84.
 73. Van De Lagemaat E, De Groot L, Heuvel ED. Vitamin B 12 in relation to oxidative stress: A systematic review. *Nutrients.* 2019;11(2):482. doi:10.3390/nu11020482.
 74. Sarhan NR, Taalab YM. Oxidative stress/PERK/apoptotic pathways interaction contribute to tramadol neurotoxicity in rat cerebral and cerebellar cortex and thyme enhances the antioxidant defense system: histological, immunohistochemical and ultrastructural study. *Int J Sci Rep.* 2018;4(6):124. doi:10.18203/issn.2454-2156.IntJSciRep20182083.


Author biography

Danielle Aparecida de Oliveira Marrafon, PG Student  <https://orcid.org/0000-0002-1529-5919>

Alessandra Oliveira Silva, PG Student  <https://orcid.org/0000-0002-7844-7430>


Ana Flávia Amorim, PG Student  <https://orcid.org/0000-0001-5453-4436>


Carlos Marcelo de Barros, PG Student  <https://orcid.org/0000-0002-1207-2867>

Ricardo Radighieri Rascado, Professor  <https://orcid.org/0000-0003-0130-3110>


Carla Speroni Ceron, Professor  <https://orcid.org/0000-0003-0130-3110>

Tiago Marques dos Reis, Professor  <https://orcid.org/0000-0002-0789-0187>

Márcia Helena Miranda Cardoso Podestá, Professor  <https://orcid.org/0000-0002-3246-1907>

Daniel Augusto de Faria Almeida, Professor  <https://orcid.org/0000-0003-1210-4985>

Larissa Helena Torres, Professor  <https://orcid.org/0000-0002-7065-7484>

Marília Gabriella Alves Goulart Pereira, Professor  <https://orcid.org/0000-0002-0894-954X>

Cite this article: Marrafon DAO, Silva AO, Amorim AF, Barros CM, Rascado RR, Ceron CS, Reis TM, Podestá MHMIC, Almeida DAF, Torres LH, Pereira MGAG. Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review. *J Pharm Biol Sci* 2023;11(1):18-25.